Dr. Daniel C. Ramirez is Interim Pathologist-in-Chief and an Attending Pathologist at HSS with special interest in the diagnosis of neoplastic and non-neoplastic conditions of bone, joints, and soft tissues.
Dr. Ramirez received his medical degree from University of Medicine and Dentistry of New Jersey - New Jersey Medical School in Newark, New Jersey. He trained in Anatomic and Clinical Pathology at Rutgers - New Jersey Medical School followed by fellowships in Surgical Oncologic Pathology at Memorial Sloan Kettering Cancer Center and Orthopedic Pathology at HSS.
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Interim Pathologist-in-Chief, Hospital for Special Surgery
Attending Pathologist, Hospital for Special Surgery
Anatomic Pathology
Clinical Pathology
Medical: University of Medicine and Dentistry of New Jersey, New Jersey Medical School, 2011
Residency: Rutgers New Jersey Medical School, 2015
Fellowships: Surgical Oncologic Pathology, Memorial Sloan Kettering Cancer Center, 2016
Orthopedic Pathology, Hospital for Special Surgery, 2017
English
Zhu GG, Ramirez D, Chen W, Lu C, Wang L, Frosina D, Jungbluth A, Ntiamoah P, Nafa K, Boland PJ, Hameed MR. Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma. Hum Pathol. 2020 Oct;104:73-83. doi: 10.1016/j.humpath.2020.07.002. Epub 2020 Aug 12. PMID: 32795465.
Gundle KR, Deutsch GB, Goodman HJ, Pollack SM, Thompson MJ, Davis JL, Lee MY, Ramirez DC, Kerwin W, Bertout JA, Grenley MO, Sottero KHW, Beirne E, Frazier J, Dey J, Ellison M, Klinghoffer RA, Maki RG. Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma. Clin Cancer Res. 2020 Aug 1;26(15):3958-3968. doi: 10.1158/1078-0432.CCR-20-0614. Epub 2020 Apr 16. PMID: 32299817.
Lu C, Ramirez D, Hwang S, Jungbluth A, Frosina D, Ntiamoah P, Healey J, Zhu G, Chen W, Klein M, Hameed M.
Histone H3K36M mutation and trimethylation patterns in chondroblastoma. Histopathology. 2019 Jan;74(2):291-299. doi: 10.1111/his.13725. Epub 2018 Nov 4. PMID: 30098026; PMCID: PMC6298805.
HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.
As of May 11, 2024, Dr. Ramirez reported no relationships with the healthcare industry.
HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.
